US Stock MarketDetailed Quotes

ANRO Alto Neuroscience

Watchlist

14.880
+0.380+2.62%

Trading Jul 16 12:01 ET

400.03MMarket Cap-9423P/E (TTM)

Alto Neuroscience Stock Forum

Jaguar8

Apr 23 07:36

$Alto Neuroscience(ANRO.US)$
NEWS
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
ALTO-101 demonstrated favorable pharmacokinetic and tolerability profile in Phase 1 study
Transdermal formulation provided significantly greater drug exposure with fewer adverse events
Proof-of-concept study for CIAS to start in the first half of 2024
Topline data expected in the second half of 2025
Achievement of target exposure with propri...

Moomoo AI

Feb 27 11:21

Investment firms see Alto Neuroscience's biomarker approach as a potential boost for clinical trials and patient outcomes. They predict a high stock risk/reward into 2H 2024/1H 2025 readouts, with a possible 100%-200% rise on positive data.